Atorvastatin in Myeloma

NCT00164086 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2006-10-11

No results posted yet for this study

Summary

The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.

Conditions

Interventions

Sponsors & Collaborators

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Andrew Spencer, MBChB, FRACP, PhD · The Alfred

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Australia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00164086 on ClinicalTrials.gov